Guisier, Florian
Inserm · Centre Hospitalier Universitaire de Rouen
3 papers on CoChatORCID 0000-0002-8166-7303
Most cited papers
- Verified
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial
Scherpereel, A., Mazieres, J., Greillier, L., Lantuejoul, S., Dô, P., Bylicki, O., Monnet, I., Corre, R., Audigier-Valette, C., Locatelli-Sanchez, M., et al. (2019) · The Lancet Oncology
Occupational and environmental lung diseasesIntraperitoneal and Appendiceal Malignancies
Cited by 454
- Verified
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
Delaunay, M., Cadranel, J., Lusque, A., Meyer, N., Gounant, V., Moro-Sibilot, D., Michot, J.-M., Raimbourg, J., Girard, N., Guisier, F., et al. (2017) · European Respiratory Journal
Cancer Immunotherapy and BiomarkersInterstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Cited by 412
- Verified
ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date
Gendarme, S., Bylicki, O., Chouaid, C., & Guisier, F. (2022) · Current Oncology
Lung Cancer Treatments and MutationsLung Cancer Research Studies
Cited by 121
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free